Insider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CFO Sells 1,785 Shares of Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CFO Howard Horn sold 1,785 shares of the stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $40.40, for a total value of $72,114.00. Following the completion of the transaction, the chief financial officer now directly owns 106,169 shares in the company, valued at approximately $4,289,227.60. This trade represents a 1.65 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Ultragenyx Pharmaceutical Price Performance

Shares of Ultragenyx Pharmaceutical stock traded down $0.91 during trading on Monday, reaching $37.71. 353,446 shares of the company traded hands, compared to its average volume of 782,014. Ultragenyx Pharmaceutical Inc. has a 1-year low of $37.02 and a 1-year high of $60.37. The firm has a market capitalization of $3.49 billion, a PE ratio of -5.96 and a beta of 0.67. The company has a 50 day moving average price of $42.57 and a 200-day moving average price of $48.63.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The firm had revenue of $164.88 million during the quarter, compared to analyst estimates of $163.23 million. Equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Piper Sandler lifted their target price on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Monday, January 13th. Wells Fargo & Company raised their price objective on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a report on Friday, December 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. Canaccord Genuity Group boosted their target price on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a report on Tuesday, February 18th. Finally, Wedbush reiterated a “neutral” rating and issued a $48.00 price target (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and an average target price of $93.50.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several large investors have recently added to or reduced their stakes in RARE. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Ultragenyx Pharmaceutical during the 4th quarter worth $5,505,000. Mackenzie Financial Corp boosted its stake in shares of Ultragenyx Pharmaceutical by 275.6% in the 4th quarter. Mackenzie Financial Corp now owns 16,115 shares of the biopharmaceutical company’s stock worth $678,000 after buying an additional 11,825 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in Ultragenyx Pharmaceutical in the fourth quarter worth $82,000. Frazier Life Sciences Management L.P. increased its position in shares of Ultragenyx Pharmaceutical by 3.9% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 658,715 shares of the biopharmaceutical company’s stock valued at $27,712,000 after purchasing an additional 25,000 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 13.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 202,376 shares of the biopharmaceutical company’s stock worth $8,514,000 after buying an additional 24,620 shares during the last quarter. Institutional investors own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.